Status:
ACTIVE_NOT_RECRUITING
NAD Supplementation and Vascular Health in PAD
Lead Sponsor:
University of Oklahoma
Conditions:
Peripheral Artery Disease
Eligibility:
All Genders
55-99 years
Phase:
PHASE1
PHASE2
Brief Summary
This pilot open-label clinical trial was designed to investigate whether 4-week supplementation with 1g daily NR impacts endothelial function in peripheral circulation, cerebrovascular hemodynamics, c...
Detailed Description
Peripheral artery disease (PAD) is a prevalent age-related vascular pathology and the third leading cause of cardiovascular morbidity and mortality among older adults. Accumulating evidence indicates ...
Eligibility Criteria
Inclusion
- diagnosis of PAD
- intermittent claudication
- limited walking capacity
Exclusion
- macologically uncontrolled type 2 diabetes, hypercholesterolemia, hypertension
- major depressive disorder
- current or prior cerebrovascular complications (including large vessel ischemic stroke with chronic functional impairment)
- neurodegenerative diseases
Key Trial Info
Start Date :
February 27 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2024
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT06534944
Start Date
February 27 2023
End Date
December 30 2024
Last Update
August 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States, 73104